Tenet Advances Portfolio Transformation and Previews Strong 2023 Results
- Completed sale of three South Carolina hospitals for approximately $2.4 billion
- Announced sale of four hospitals in California for approximately $975 million
- Expected to exceed the high end of its latest FY23 Adjusted EBITDA Outlook range
- Estimates a pre-tax book gain of approximately $500 million from the anticipated transaction
- The sale of the four hospitals in California generated revenues of approximately $1 billion, pre-tax income of approximately $29 million, and Adjusted EBITDA of approximately $71 million
- The transactions will support Tenet’s objective of reducing leverage
- The company's actual results for the year ended December 31, 2023, may differ from preliminary estimates
The divestiture of Tenet Healthcare's South Carolina hospitals for $2.4 billion and the pending sale of its California hospitals for $975 million represent significant portfolio restructuring. The after-tax proceeds of these transactions amount to approximately $1.750 billion and $800 million, respectively, which signal a substantial liquidity infusion. This capital reallocation is likely to bolster Tenet's balance sheet and support its debt reduction goals.
The expected surge in Adjusted EBITDA above the forecasted range indicates operational efficiency and could be a positive signal for investors regarding Tenet's financial health. Moreover, the estimated pre-tax book gain of $500 million from the California transaction, coupled with the favorable tax impact estimated at $190 million, suggests a robust financial position for Tenet in the near term.
However, the sale of assets also means a reduction in Tenet's operational size, which could impact future revenue streams. The strategic focus seems to be on optimizing the portfolio for profitability rather than expansion. Investors should consider the potential long-term implications of a smaller operational footprint on revenue growth.
The sale of Tenet's hospitals to entities like Novant Health and UCI Health reflects a trend in the healthcare industry towards consolidation. Novant's acquisition enhances its presence in South Carolina, while UCI Health's purchase aligns with its academic health system expansion goals, potentially improving access to specialized medical care in Orange and Los Angeles Counties.
Conifer Health Solutions' expanded fifteen-year contract to provide revenue cycle management services for the South Carolina operations underlines the importance of efficient billing and collections in healthcare. This long-term agreement should provide a stable revenue stream for Tenet post-divestiture.
For stakeholders, the transactions may offer improved healthcare access and quality due to the academic affiliations and resources of UCI Health. However, there is always a risk of integration challenges and cultural shifts that could affect patient care and employee satisfaction during such transitions.
Assessing Tenet's divestiture within the context of the healthcare market, we observe a strategic pivot towards optimizing operations. The revenue generated from the South Carolina and California hospitals, approximately $1 billion, with an Adjusted EBITDA of $71 million, indicates a modest profit margin.
The transaction's timing is also noteworthy, with healthcare providers facing various challenges such as regulatory changes and payment model shifts. Tenet's decision to sell these assets may be a proactive measure to navigate these complexities more effectively.
Market trends suggest that healthcare providers are increasingly focusing on core competencies and high-margin services. Tenet's strong surgical growth at USPI could indicate a strategic emphasis on outpatient and ambulatory services, which are typically more profitable than inpatient care.
Tenet completes sale of three
Tenet completed the sale of its three
Additionally, Tenet has entered into a definitive agreement with UCI Health for the sale of four Tenet hospitals and related operations in
“Our four hospitals have provided high-quality care for
For the year ended December 31, 2023, the four hospitals and related operations included in the sale generated revenues of approximately
The transaction is expected to be completed in the spring of 2024, subject to customary regulatory approvals, clearances, and closing conditions.
In addition, Tenet estimates that as a result of the pre-tax book gains from these two transactions, the Company’s income tax expense would be favorably impacted in 2024 by approximately
Although Tenet’s financial statement close process is not yet fully completed, the Company currently estimates that its Adjusted EBITDA for the year ended December 31, 2023, will be above the high end of its current Adjusted EBITDA guidance range after normalizing for the recognition of
“Our team continues to deliver consistently strong results, driven by Tenet’s data-driven and disciplined operating model,” said Sutaria. “We look forward to providing more details on our performance when we announce our complete fourth quarter and full year results on February 8, 2024.”
The Company’s actual results for the year ended December 31, 2023 may differ from such preliminary estimates and additional developments and adjustments may arise between now and the time the financial information for this period is finalized. Accordingly, you should not place undue reliance on these estimates.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in
Non-GAAP Financial Measures
The Company has not finalized all the data to be able to reconcile certain forward-looking non-GAAP financial measures to the most comparable
Reconciliations of non-GAAP measures, such as Adjusted EBITDA, to the most comparable GAAP measures and management’s reasoning for using them are included in the Company’s earnings press release dated October 30, 2023, which is available on the investor relations section of the Company’s website at www.tenethealth.com/investors. Investors are encouraged to read these detailed financial disclosures and reconciliations.
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131816114/en/
Investor Contact
Will McDowell
469-893-2387
William.McDowell@tenethealth.com
Media Contact
Robert Dyer
469-893-2640
mediarelations@tenethealth.com
Source: Tenet Healthcare Corporation
FAQ
How many hospitals did Tenet Healthcare Corporation sell in South Carolina?
What is the expected pre-tax book gain from the anticipated transaction with UCI Health?
What is the ticker symbol for Tenet Healthcare Corporation?
